Full Press Release Details
accelr892509exh991.txt
[COMPANY LOGO GRAPHIC OMITTED]
Accelr8 and Becton Dickinson Conclude
Technical Development Project
DENVER, Colo., September 25, 2009 - Accelr8 Technology Corporation
(Alternext-US:AXK) announced today that it has concluded a technical development
project with Becton, Dickinson and Company ("BD," NYSE: BDX). Accelr8's
technology met formal testing requirements for identification of a subset of
relevant species of bacteria. However, BD advised the Company that it has
decided to decline an associated exclusive technology license option. At any
time, BD has numerous new product opportunities, and prioritizes projects on the
basis of decision criteria that are not limited to technical factors.
According to David Howson, Accelr8's president, "we're disappointed by BD's
decision not to exercise its exclusive option. Nevertheless, we made substantial
advances and gained strong supporting technical evidence in the project,
including integrated testing using patient specimens. We will continue
discussions with other prospective collaborators. The BACcel(TM) rapid
diagnostic system remains the only technology yet supported by published data to
have the capability to provide same-day analysis of all significant highly
drug-resistant bacteria and their particular resistance mechanisms."
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation and biosciences basic research. Accelr8 is developing a rapid
clinical pathogen diagnostic platform, the BACcel(TM), based on its wholly-owned
intellectual property. In addition, Accelr8 licenses certain of its proprietary
technology for use in applications outside of Accelr8's own products.
--------------------------------------------------------------------------------
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve certain
risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking statement,
including those detailed in the company's filings with the Securities
and Exchange Commission. Accelr8 does not undertake an obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information or future events.
--------------------------------------------------------------------------------
John Metzger, of Metzger Associates
+1.303.786.7000, ext. 2202
Tom Geimer, of Accelr8 Technology Corp.